Inhaled Medication Use in Smokers With Normal Spirometry.
COPD
empiric treatment
respiratory function tests
smoking
spirometry
Journal
Respiratory care
ISSN: 1943-3654
Titre abrégé: Respir Care
Pays: United States
ID NLM: 7510357
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
pubmed:
11
2
2021
medline:
27
4
2021
entrez:
10
2
2021
Statut:
ppublish
Résumé
The objective of our study was to identify variables associated with inhaled medication use in smokers with normal spirometry (GOLD-0) and to examine the association of inhaled medication use with development of exacerbations and obstructive spirometry in the future. We performed a retrospective multivariable analysis of GOLD-0 subjects identified in data from the COPDGene study to examine factors associated with medication use. Five categories were identified: (1) no medications, (2) short-acting bronchodilator, (3) long-acting bronchodilator; long-acting muscarinic antagonists and/or long-acting β agonist, (4) inhaled corticosteroids (ICS) with or without long-acting bronchodilator, and (5) dual bronchodilator with ICS. Sensitivity analysis was performed excluding subjects with history of asthma. We also evaluated whether long-acting inhaled medication use was associated with exacerbations and obstructive spirometry at the follow-up visit 5 y after enrollment. Of 4,303 GOLD-0 subjects within the analysis, 541 of them (12.6%) received inhaled medications. Of these, 259 (6%) were using long-acting inhaled medications and 282 (6.6%) were taking short-acting bronchodilator. Female sex (odds ratio [OR] 1.47, Respiratory symptoms, history of asthma, and radiographic emphysema were associated with inhaled medication use in smokers with normal spirometry. These individuals were more likely to develop obstructive spirometry, which suggests that health care providers may be able to identify obstructive lung disease prior to meeting the current criteria for COPD.
Sections du résumé
BACKGROUND
BACKGROUND
The objective of our study was to identify variables associated with inhaled medication use in smokers with normal spirometry (GOLD-0) and to examine the association of inhaled medication use with development of exacerbations and obstructive spirometry in the future.
METHODS
METHODS
We performed a retrospective multivariable analysis of GOLD-0 subjects identified in data from the COPDGene study to examine factors associated with medication use. Five categories were identified: (1) no medications, (2) short-acting bronchodilator, (3) long-acting bronchodilator; long-acting muscarinic antagonists and/or long-acting β agonist, (4) inhaled corticosteroids (ICS) with or without long-acting bronchodilator, and (5) dual bronchodilator with ICS. Sensitivity analysis was performed excluding subjects with history of asthma. We also evaluated whether long-acting inhaled medication use was associated with exacerbations and obstructive spirometry at the follow-up visit 5 y after enrollment.
RESULTS
RESULTS
Of 4,303 GOLD-0 subjects within the analysis, 541 of them (12.6%) received inhaled medications. Of these, 259 (6%) were using long-acting inhaled medications and 282 (6.6%) were taking short-acting bronchodilator. Female sex (odds ratio [OR] 1.47,
CONCLUSIONS
CONCLUSIONS
Respiratory symptoms, history of asthma, and radiographic emphysema were associated with inhaled medication use in smokers with normal spirometry. These individuals were more likely to develop obstructive spirometry, which suggests that health care providers may be able to identify obstructive lung disease prior to meeting the current criteria for COPD.
Identifiants
pubmed: 33563793
pii: respcare.08016
doi: 10.4187/respcare.08016
pmc: PMC9993991
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Adrenergic beta-2 Receptor Agonists
0
Bronchodilator Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
652-660Subventions
Organisme : RRD VA
ID : IK2 RX002165
Pays : United States
Informations de copyright
Copyright © 2021 by Daedalus Enterprises.
Déclaration de conflit d'intérêts
This work was supported in part by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. Dr Hersh has disclosed relationships with Bayer, Boehringer-Ingelheim, Novartis, and Vertex. Dr Comellas has disclosed a relationship with GlaxoSmithKline. Dr Fortis has disclosed relationships with the American Thoracic Society and Fisher & Paykel. The remaining authors have no disclosed no conflicts of interest.
Références
Int J Chron Obstruct Pulmon Dis. 2015 Jul 21;10:1409-16
pubmed: 26229460
Respir Res. 2018 Oct 29;19(1):209
pubmed: 30373671
Am J Respir Crit Care Med. 2016 Aug 1;194(3):249-50
pubmed: 27479055
J Crit Care. 2012 Aug;27(4):425.e1-8
pubmed: 22172793
BMC Neurol. 2018 Dec 21;18(1):215
pubmed: 30577762
Chest. 2011 Sep;140(3):626-633
pubmed: 21474571
J Epidemiol Community Health. 2000 Dec;54(12):917-22
pubmed: 11076988
Respir Physiol Neurobiol. 2019 Mar;261:55-61
pubmed: 30658095
COPD. 2010 Feb;7(1):32-43
pubmed: 20214461
Eur Respir J. 2017 May 1;49(5):
pubmed: 28461294
Chest. 2015 Feb;147(2):369-376
pubmed: 25079684
AJR Am J Roentgenol. 2013 Sep;201(3):W460-70
pubmed: 23971478
Respir Res. 2014 Apr 27;15:52
pubmed: 24766722
N Engl J Med. 2016 May 12;374(19):1842-1852
pubmed: 27168434
Chest. 2014 Dec;146(6):1513-1520
pubmed: 24763942
Chest. 2019 Aug;156(2):277-288
pubmed: 30711480
Eur Respir J. 2015 Mar;45(3):635-43
pubmed: 25431272
BMC Fam Pract. 2016 Mar 31;17:38
pubmed: 27036116
Allergy. 2007 Jun;62(6):591-604
pubmed: 17508962
Eur Respir J. 2019 May 18;53(5):
pubmed: 30846476
Am J Respir Crit Care Med. 2013 Feb 1;187(3):228-37
pubmed: 23204254
BMC Pulm Med. 2013 Nov 22;13:68
pubmed: 24266961
PLoS One. 2019 Feb 4;14(2):e0211532
pubmed: 30716129
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Respir Care. 2016 Sep;61(9):1192-200
pubmed: 27165420
N Engl J Med. 2016 May 12;374(19):1811-21
pubmed: 27168432
Ann Intern Med. 2014 Dec 16;161(12):863-73
pubmed: 25506855
Chronic Obstr Pulm Dis. 2019 Nov;6(5):384-399
pubmed: 31710793
Am J Respir Crit Care Med. 2015 Jun 15;191(12):1384-94
pubmed: 25826478
Ann Am Thorac Soc. 2019 Jul;16(7):826-835
pubmed: 30908927
N Engl J Med. 1998 Oct 22;339(17):1194-200
pubmed: 9780339
Am J Respir Crit Care Med. 2007 Jul 15;176(2):113-20
pubmed: 17413125
Radiology. 2015 Oct;277(1):192-205
pubmed: 25961632
Fam Pract. 2008 Apr;25(2):86-91
pubmed: 18304973
Br J Gen Pract. 2017 Apr;67(657):183-184
pubmed: 28360069
Chest. 2006 Jan;129(1):15-26
pubmed: 16424409
N Engl J Med. 2017 Sep 7;377(10):923-935
pubmed: 28877027
Thorax. 2008 May;63(5):402-7
pubmed: 18234906
JAMA. 2008 Sep 24;300(12):1439-50
pubmed: 18812535
JAMA Intern Med. 2015 Sep;175(9):1539-49
pubmed: 26098755
Ann Behav Med. 2016 Jun;50(3):348-57
pubmed: 26631086
Clinicoecon Outcomes Res. 2013 Jun 17;5:235-45
pubmed: 23818799
Health Qual Life Outcomes. 2006 Sep 28;4:72
pubmed: 17007639
Am J Respir Crit Care Med. 2017 Feb 1;195(3):324-330
pubmed: 27556408